Protocol ARC003: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (The Palisade Study)
Sponsor: |
Aimmune Therapeutics, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ5204 |
U.S. Govt. ID: |
NCT02635776 |
Contact: |
Elizabeth Duverger: 929-280-5799 / ed2714@cumc.columbia.edu |
This is an experimental research study for individuals with allergy to peanuts or peanut-containing food. Oral (by mouth, not injection) immunotherapy may reduce a patients sensitivity to a specific allergen by exposing the patient to small amounts of the substance causing the allergic reaction and then gradually increasing the amount of allergen over time. Although immunotherapy does not cure an allergy, for many, it lessens the bodys sensitivity to the allergen, resulting in fewer symptoms.
This study is closed
Investigator
Joyce Yu, MD
Do you have a clinical history of allergy to peanuts or peanut-containing foods? |
Yes |
No |